Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contraceptive choices--turning back the clock.

E Weisberg1

  • 1Family Planning Association of New South Wales, Ashfield, Australia.

Advances in Contraception : the Official Journal of the Society for the Advancement of Contraception
|June 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

British journal of cancer·2019
Same author

The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression.

Leukemia·2012
Same author

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Leukemia·2012
Same author

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

Leukemia·2011
Same author

The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.

Leukemia·2011
Same author

Smac mimetics: implications for enhancement of targeted therapies in leukemia.

Leukemia·2010

Contraceptive options are declining globally due to complex commercial, liability, and regulatory issues. This impacts accessibility and availability of reproductive health services for individuals worldwide.

Area of Science:

  • Reproductive Health
  • Public Health Policy
  • Pharmaceutical Economics

Background:

  • Global contraceptive choices are diminishing, contrary to expectations of expanding options.
  • This trend, particularly evident in Western nations, stems from multifaceted commercial and regulatory challenges.

Purpose of the Study:

  • To analyze the complex factors contributing to the reduction in contraceptive availability.
  • To examine the impact of commercial interests, liability concerns, and regulatory hurdles on contraceptive markets.

Main Methods:

  • The study presents an Australian perspective, drawing on shared concerns from international family planning experts.
  • Analysis incorporates commercial considerations, media influence, liability issues, insurance costs, marketing expenses, and regulatory delays.

Related Experiment Videos

Main Results:

  • Commercial interests are a primary driver behind reduced contraceptive options.
  • Increased insurance costs (product liability and medical liability) raise contraceptive prices and limit service availability (e.g., IUD insertions, sterilization).
  • High marketing costs, regulatory delays, and socio-political influences (e.g., feminist, consumer, anti-abortion groups) further restrict contraceptive development and market entry.

Conclusions:

  • The reduction in contraceptive choices is a complex issue driven by economic, legal, and political factors.
  • Addressing these challenges requires a multi-pronged approach to ensure continued access to reproductive health services.
  • Potential solutions are proposed to mitigate these barriers and improve contraceptive availability.